Risks of Unapproved Peptide Products

The gap between online availability and legal supply is enormous

Forty-seven enforcement actions. That's how many TGA regulatory actions specifically targeting unapproved and illegally supplied peptide products the agency recorded across a recent two-year reporting window. Forty-seven, and that number only counts what the TGA formally actioned , not the grey-market listings that slipped through, the "research use only" loopholes people quietly wink at, or the vials that arrived in a padded envelope from overseas.

I've been writing about peptide pharmacology long enough to know the disconnect is real. The molecules themselves are genuinely interesting , short chains of amino acids linked by peptide bonds, structurally diverse, with receptor-binding profiles that have attracted serious pharmaceutical research for decades. The problem isn't the science. The problem is a market that has far outrun the regulatory frameworks designed to protect people from unverified chemistry injected under the skin.

What "unapproved" actually means in Australian law

Australia's therapeutic goods framework requires that any product intended to influence a physiological process in humans must be listed or registered on the Australian Register of Therapeutic Goods , the ARTG; before it can be lawfully supplied. Full stop.

A peptide sold commercially as a "research chemical" or with a "not for human use" disclaimer does not escape this requirement if the product is, in practice, supplied with the expectation of human administration. The TGA has stated this plainly in guidance. The label on the vial is not a legal shield.

Most peptides being sold through gym networks, social media channels, and overseas online retailers fall into one of two uncomfortable categories: either they have never been evaluated for human safety at all, or they are Schedule 4 (prescription-only) medicines under the Poisons Standard, meaning they can only be lawfully supplied to an individual with a valid prescription from an authorised prescriber. Some compounds sit under Schedule 8 controlled drug provisions, carrying even heavier supply restrictions. Bypassing that is not a technicality. It is a criminal offence under the Therapeutic Goods Act 1989.

For peptides that are prescription-only, Schedule 4 under the Poisons Standard; legal access requires a licensed medical practitioner, a genuine clinical assessment, and a compounding pharmacist operating under Good Manufacturing Practice standards. The Special Access Scheme and Authorised Prescriber pathways exist specifically to allow access to unapproved therapeutic goods in circumstances where a medical case can be made. Purchasing from a website is not one of those circumstances.

Why the pharmacology of unapproved products is genuinely unpredictable

Here's the part that keeps me up at night, professionally speaking, not because I mainline true crime podcasts at midnight (okay, sometimes that too).

When a peptide compound is sourced outside the regulated supply chain, you lose the foundational guarantees of pharmaceutical manufacturing. Identity, purity, potency, and sterility, these are not marketing terms. They are the properties that determine whether a compound does what its molecular structure suggests it should, or whether it does something else entirely.

Independent laboratory analyses of grey-market peptide products have repeatedly found discrepancies between labelled and actual content. Some vials contain less active compound than stated. Others contain more. Some contain microbial contamination consistent with non-sterile manufacturing environments. A handful have contained entirely different compounds to those on the label.

The pharmacokinetics of peptide compounds; their absorption, distribution, metabolism, and elimination profiles, are highly sensitive to molecular integrity. A peptide with even minor structural modifications from incorrect synthesis behaves differently at its target receptor. And most of these compounds are administered via subcutaneous injection, which bypasses the gut's considerable capacity to degrade foreign material before it reaches systemic circulation. There is no first-pass filter here; whatever is in that vial goes directly into the bloodstream.

Take GLP-1 analogues as a concrete example. Compounds that interact with the GLP-1 receptor have a well-characterised safety and dosing profile when manufactured under pharmaceutical GMP, dispensed with a prescription, and used under medical supervision. The same receptor engagement from an impure, misdosed, or contaminated vial of unknown provenance creates an entirely different risk profile. The receptor is the same; the context is not.

TGA enforcement: what it looks like in practice

The TGA has been direct about this. Their published guidance on compounded peptides explicitly warns that products such as certain growth hormone-related peptides and related compounds are not approved for therapeutic use in Australia, that legitimate compounding for these products is severely restricted or prohibited, and that the agency has taken enforcement action, including issuing infringement notices, seeking injunctions, and referring matters for prosecution; against suppliers operating outside the law.

In 2023 and 2024, TGA compliance activity specifically flagged the proliferation of peptide products being marketed for body composition, performance, and anti-ageing purposes. These are areas where no product in this class holds current ARTG approval for those indications. Supplying them for those purposes, with or without a label claiming otherwise, is not a regulatory grey area. It is illegal supply, and the penalties under the Therapeutic Goods Act 1989 include substantial fines and imprisonment.

I'd argue, honestly, that the "research chemical" framing frustrates me more than almost any other regulatory dodge in this space. It is technically meaningless as a consumer protection, and everyone involved in the supply chain knows it.

What the risks to the individual actually look like

Setting legality aside for a moment and looking purely at the pharmacological risk profile: unapproved peptide use via non-sterile, unverified products can expose a person to injection-site infections, systemic bacteraemia from contaminated preparations, immune reactions to impurities or carrier solvents, dose-dependent adverse effects compounded by unknown potency, and interactions with other substances that no prescriber has had the opportunity to assess.

Because access has occurred outside the medical system, adverse events are less likely to be reported, less likely to be correctly attributed, and less likely to inform future safety understanding. That's a systemic problem, not just an individual one. The pharmacovigilance infrastructure that catches problems with approved medicines simply doesn't function for products that were never in the regulated system to begin with.

There is also the question of what happens downstream. Peptide compounds that act on endocrine or metabolic pathways can influence systems that interact with other regulatory axes in ways that aren't always immediately apparent. Some compounds with growth hormone secretagogue activity, for example, have known effects on glucose metabolism and insulin sensitivity. Without baseline assessment and monitoring, those effects go unobserved until they become clinically obvious, sometimes in an emergency department.

How legitimate access pathways actually work

For completeness: where peptide compounds do have an established evidence base and a prescriber is willing to make a clinical case, the SAS and Authorised Prescriber frameworks provide legal pathways. These are not quick or casual processes. They require a genuine prescriber-patient relationship, documentation of clinical rationale, and; in the case of compounded preparations, a compounding pharmacist operating to TGA-recognised GMP standards.

The bioavailability of peptides administered via different routes is also a critical consideration in clinical dosing that a legitimate prescriber factors in. Subcutaneous versus intramuscular administration, the excipient profile of a compounded preparation, storage conditions, all of these affect what the body actually receives. None of that rigour exists outside the supervised supply chain.

The short version is this: if a peptide compound is available to you without a prescription and without a documented clinical assessment, the supply is almost certainly illegal, and the product has not been verified for safety by any Australian regulatory authority. Those two facts compound each other.

Sources

• Compounded peptides guidance; Therapeutic Goods Administration (TGA)
• Good Manufacturing Practice, Therapeutic Goods Administration (TGA)
• Peptide drug discovery and pharmacology, NCBI Bookshelf, National Library of Medicine
• Therapeutic Goods Act 1989 overview; Australian Department of Health and Aged Care

, Priya Nandakumar, Pharmacology writer, peptides & PK